Modis Therapeutics
Acquired by Zogenix
Develops targeted therapies for rare genetic diseases and mitochondrial disorders.
Develops targeted therapies for rare genetic diseases and mitochondrial disorders.
Investment Team
Sector
Life SciencesCategory
TherapeuticsLocation
Oakland, CAInitial Investment
2018Modis Therapeutics, Inc. was formed in 2016 through a collaboration with academic experts in mitochondrial biology. The company’s lead program (MT1621) is in clinical development for thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disease. Modis Therapeutics is headquartered in Oakland CA, with offices in New York City. Modis was acquired by Zogenix.